Top 10 AI Agents forMedical Practices in 2026

The claim that sells almost every AI product into a medical practice is that it saves clinicians about two hours a day. The best independent evidence measures the benefit in minutes. A randomised crossover clinical trial published in the Journal of the American Medical Informatics Associationin 2026 — 33(5):990–999, 160 clinicians enrolled and 136 analysed — compared two ambient scribe products head to head and found reductions in time-in-notes of 5.89 and 9.07 minutes per day. It found no meaningful reduction in after-hours work, the pajama time that drives most of the burnout conversation, for either product.

That is not a debunking. The same trial found something genuinely valuable: both tools reduced personal and work-related burnout on the Copenhagen Burnout Inventory, with no meaningful difference between them, and safety concerns were minimal — though users emphasised the need for careful note editing. Workflow satisfaction improved more with one product than the other, by 0.60 points on a seven-point scale. The trial identifies the two products only as Product A and Product B, so nobody can honestly attach a vendor name to those results, and we will not.

The second claim under test is economic rather than clinical. The Peterson Health Technology Institute assessed ambient scribes across eight large health systems — CommonSpirit Health, Intermountain Health, Mass General Brigham, MultiCare, Ochsner Health, Providence, UC San Diego Health and Yale New Haven Health — and published its findings on 25 March 2025. The conclusion was that AI-powered scribes likely improve clinician burnout but that the financial impact is unclear. That is the closest thing to an independent economic evaluation this category has, and it comes from organisations with more measurement capacity than any independent practice will ever have. If they could not demonstrate a clear financial return, a six-provider group should be sceptical of a vendor who promises one on a slide.

So this article does something different from the rankings you have already read. It does not score accuracy, because no independent benchmark of these products exists — not one, for any product in this market. It scores what a practice owner can verify without leaving their desk: what integrations the vendor publishes, what certifications sit on a page you can open, whether a BAA is offered publicly, whether a price is published at all, whether the product is standalone or locked to a suite, and who owns the company today according to public record. Every cell in the table below carries a citation or the literal words not publicly disclosed, and every one of them is re-checkable on the day you sign. That is more than any competing list can say about a single accuracy figure.

If you want the wider framing before the vendor-by-vendor detail, our cross-industry review of AI agents in 2026 applies the same refusal-to-score-marketing method across ten verticals, and the pattern holds everywhere: the read surface is wide, the write surface is narrow, and the numbers that sell the software are the ones nobody has audited.

We scored eight attributes, every one of which a reader can re-check at a public URL, and we refused to score anything a vendor publishes about its own performance. That refusal is not modesty. It is the only defensible position available, because in this market every accuracy, deflection, containment, resolution-rate and ROI figure in circulation was published by the company selling the software, without a methodology, a denominator or a third-party audit.

What an independent benchmark would look like, and what exists instead

No independent benchmark of accuracy, deflection, containment or resolution rate exists for any AI agent sold to medical practices. That is a precise claim, not a blanket denial, and the distinction matters because independent evaluation in this vertical genuinely does exist — it just does not measure the thing vendors are selling. Three things exist and should not be confused with one another.

• Peer-reviewed randomised trials of the modality: The JAMIA 2026 crossover trial is real, randomised, independent of the vendors, and measures minutes-in-notes and burnout. It tells you what ambient scribing does. It does not tell you which product to buy, because the products are anonymised as Product A and Product B.
• An independent economic assessment: The Peterson Health Technology Institute's March 2025 assessment across eight large health systems concluded that scribes likely improve burnout while the financial impact is unclear. It is an assessment of a category, not a ranking of vendors, and the announcement page carries no percentages — so no percentage should be attributed to it.
• A customer-satisfaction survey: Best in KLAS 2026, released 4 February 2026, ranked Abridge first in Ambient AI at 94.7 points with Ambience second at 94.4, and CodaMetrix first in Autonomous Coding. KLAS is a third-party research firm surveying customers about satisfaction. It is not a measurement of what the software outputs. A vendor can rank first in KLAS and still have published no accuracy measurement at all — which is exactly the situation here.

What happened the one time a regulator audited a vendor's AI metrics

There is a reason to hold vendor performance numbers at arm's length that is stronger than professional caution: the one time a US federal regulator audited a public company's published AI performance metrics, it found them materially misleading. In In the Matter of Presto Automation Inc., Securities Act Release No. 11352, Exchange Act Release No. 102177, Admin. Proc. File No. 3-22413, entered 14 January 2025, the SEC addressed a drive-thru voice AI product the company had told investors delivered “over 94% accuracy even in noisy environments” and 95%–99% automated order completion.

The product “lacked the capability to take orders on their own and required substantial human involvement,” with “human order takers located abroad (primarily in the Philippines and India), who processed the vast majority of drive-thru orders.”

— SEC, In the Matter of Presto Automation Inc., Release No. 33-11352 (14 January 2025), ¶3

Four things must be said precisely about that order, because it is frequently mis-summarised. Presto consented without admitting or denying the findings. The remedy was a cease-and-desist order with no civil penalty — it was not a fine. The findings are against Presto only; the order's “Supplier A” is Hi Auto, against whom the SEC made no findings whatsoever. And Presto Automation Inc. is a different entity from Presto Phoenix Inc., which acquired assets in December 2024.

The lesson generalises cleanly to healthcare. This is what happened the one time anyone independently checked whether a vendor's published AI performance metric described the product it was sold as describing. It is why we score only what a buyer can verify, and why the most useful question you can ask a healthcare AI vendor is not “what is your accuracy rate” but “who measured it, against what denominator, and can I see the methodology.”

The numbers we refuse to print

Several figures dominate the sales conversation in this category and none of them should travel. We list them here so that you recognise them when a vendor puts one in a deck, and so that you can ask the one question that ends the conversation: what is the primary source?

Claims we identified and refused during this review, checked 23 August 2026. Each is named rather than silently omitted, so a reader can recognise it in the wild.

Two price-shaped refusals belong in the same category. Third-party review and reseller sites publish per-user monthly figures for Suki, Nabla and Microsoft Dragon Copilot; none of those is a vendor-published price, they vary widely between sources, and we do not reprint them. EHR-integration consultancies circulate an annual figure for Epic's Vendor Services programme; Epic does not publish it, so neither do we. In both cases the honest cell is not publicly disclosed, and a buyer should treat any article that prints a confident number as one that copied a review site.

The no-show economics deserve their own note because they are the single most common justification offered for a patient phone agent. We work through why those figures fail and what a practice can measure instead in our analysis of scheduling agents and no-show claims. The short version: build the business case on your own historical no-show rate and your own fill rate, both of which you already have, rather than on an industry figure whose denominator nobody has ever published.

Here is the entire ranking in one table, with a citation or the words “not publicly disclosed” in every cell. Nothing in it is our opinion of output quality, because output quality is exactly what nobody has measured. The ordering reflects how much of a buyer's due diligence each vendor makes possible before a sales call, which is the only proxy available and is more honest than a fabricated score.

All cells read off the vendor's own pages on 23 August 2026. Blank is never assumed — where a vendor does not publish something, the cell says so.

Read the table in two directions. Down the pricing column it tells you how much of this market expects you to enter a sales process before learning a number — which is a strategy choice, not a scandal, but it is a cost you should price into your evaluation timeline. Across the integrations column it tells you something more actionable: the vendors that name specific practice-management systems are the ones built for an independent practice, and the vendors that name only Epic are built for health systems that happen to sell to you as well.

One column deserves a warning. “Certifications on a reachable vendor page” is a measure of disclosure, not of security. A vendor with an empty cell may well hold a SOC 2 report behind a sales NDA. What the empty cell tells you is that you will have to ask, that you should ask early, and that the answer belongs in the contract rather than in an email.

Six of the ten are ambient documentation products, and every one of them is a copilot rather than an agent — it drafts, and a clinician signs. Nothing enters the record unattended in any of them. That is not a weakness in the products; it is the correct design given the constraint explained further down this page, and a vendor claiming otherwise is either running inside the EHR or overselling.

The other four are the products that are genuinely agentic — on the conversation leg. A patient phone agent holds a conversation, applies rules and reaches an outcome without a human in the loop, which is real autonomy. What happens next, when that outcome has to become a row in your schedule or your billing system, is bounded by the same constraint that bounds the scribes. The correct mental model is autonomous conversation, discretionary write.

Several of the best-known names in healthcare AI appear in “best agents for medical practices” lists and cannot be bought by a medical practice. Every company below is real and confirmed trading as of 23 August 2026. None of them belongs in this ranking, and saying why is more useful to a practice owner than three more table rows would have been.

Group one: they sell to your payer, not to you

• Cohere Health: Independent; a $90M Series C led by Temasek in May 2025, around $200M total, and it acquired ZignaAI in September 2025 — another dead name to know. It sells prior-authorisation technology to health plans. A practice experiences Cohere from the other side of a payer portal and cannot buy it. Its published speed and volume figures are vendor claims about a payer-side product and appear nowhere in this article as fact.
• Anterior: Independent; $40M announced February 2026 from Sequoia, NEA, FPV and Kinnevik, $64M total since 2023, with deployments at a health plan and an integration with HealthEdge. It automates utilisation-management review — which is to say, it automates the other side of your prior authorisation. Its chief executive's estimate of how much prior-auth administrative work language models can absorb has been widely repeated as a finding; it is an executive's estimate, and we treat it as one.
• Infinitus Systems: Independent, not acquired, around $103M raised. Its own site lists more than fifty clients dominated by payers and pharmaceutical companies — UnitedHealthcare, Aetna, Optum, Amgen, Novartis, Pfizer. Provider-facing agents exist, but the centre of gravity is payer and life sciences, and no compliance certification appears on the homepage.

Group two: they require a health system or an EHR licence

• CodaMetrix: The compliance benchmark for this entire market and unbuyable by a practice. Its own site publishes SOC 2 Type II, HITRUST and AWS badges — the only HITRUST mark in this whole review — and it was ranked first in Best in KLAS 2026 for Autonomous Coding. It was spun out of Mass General Brigham in 2019 and serves large health systems exclusively, with no ambulatory-practice offering. Use it as the standard against which you measure the vendor selling to you: if CodaMetrix can publish HITRUST and SOC 2 Type II, asking your vendor why it publishes neither is a fair question.
• Latent Health: Independent, with an $80M Series A co-led by Spark Capital and Transformation Capital around March 2026, and growth from four to more than forty-five health-system partners. Enterprise health systems only. Note one detail: the thirteen-hours-a-week prior-authorisation figure that appears in its press coverage is real and independently sourceable to the AMA survey — so cite the AMA, which measured it, rather than the vendor that repeated it.
• Epic's own agents — Art, Penny and Emmie: Introduced as persona-based agents at HIMSS 2026 alongside a no-code agent-building tool for customers. They require an Epic licence and are structurally unavailable to most independent practices. The customer figures presented on the conference stage — discharge-summary speed, prior-auth submission time, billing-message reduction — are conference anecdotes without published methodology and are not repeated here. Their real value to a practice owner is the opposite of what they were meant to demonstrate: Epic's own agents can write to Epic, and yours cannot on the same terms. That is the constraint in the next section, illustrated by the vendor that owns it.

Group three: real products we considered and did not rank

Eight more products were checked and left out of the ten. Each exclusion has a reason a reader can evaluate, and in several cases the product may be right for you even though it did not survive a disclosure-based ranking.

• Heidi Health: Independent, with a $16.6M Series A follow-on announced 26 June 2026 led by Headline, and a free tier. Left out because disclosure is thin where it counts: its pricing page publishes tier names (Free, Clinician, Teams, Enterprise) but the dollar amounts did not render when we checked, and SOC 2 and ISO 27001 are not stated on that page — only HIPAA and GDPR are referenced. It is also Melbourne-domiciled, which is a real evaluation factor for a US practice because it changes the BAA and discovery posture. Worth a trial, not a table row.
• DeepScribe: Independent and active, around $60M raised, with a 2026 push into oncology including a Flatiron Health partnership and a named cancer-centre deployment. Left out on process grounds: we could not fetch its own trust and pricing pages before publication, and filling those cells from review sites would have broken the rule this article is built on.
• Parakeet Health: Active, with patient-access automation across voice, SMS, fax and email and named deployments including a large dermatology group. Left out for a reason an operator can check independently: a $3M seed in October 2024 and no further round found as of 23 August 2026, in a category where a direct competitor just raised $120M. That is a material continuity risk for a practice signing a multi-year contract. Watch it; do not sign a three-year term yet.
• Notable: Independent, around $123M raised across four rounds, roughly 258 employees, with no new round found in 2026. It markets an AI agent workforce across patient access, revenue cycle and contact centre. Left out because it publishes almost nothing checkable: no named integrations behind its connector hub, no explicit HIPAA claim on the homepage, and a SOC 2 badge whose type is unspecified. It also predates the agent era, and the RPA-and-workflow lineage is visible in the language.
• Tennr: Independent, with a $101M Series C led by IVP in June 2025 and outbound calling added in 2026. Its own description is honest in a useful way — it classifies and routes inbound patient data from any source including fax, portal and internal order — because it tells you that the referral problem is a document problem. Left out because it names no integrations at all on its own site, which for a product whose entire value is moving data between systems is a notable gap, and because its badge reads SOC II without specifying a type.
• healow Genie (eClinicalWorks): Actively marketed in 2026 and structurally interesting: an EHR vendor's own contact-centre agent does not need the certified API, because it is already inside the walls. That is the strongest argument in this whole market for a suite-native agent. Left out because it is suite-locked in practice while marketed as EHR-agnostic — two claims that sit awkwardly together — and because no compliance claim appears on the product page. If you are an eClinicalWorks practice, evaluate it first anyway; the constraint that limits everyone else does not apply inside the suite.
• Commure: The second acquisition trap in this market. Commure acquired Athelas in 2023, then Augmedix — previously NASDAQ-listed as AUGX — in 2024, and Memora Health in December 2024. On commure.com today, Augmedix survives only inside a historical customer quote and Athelas only as a product name. Any 2026 list ranking Augmedix or Memora Health as live independent products is ranking dead names. Left out because it claims 60-plus EHR integrations without naming one, and no certification is stated on the homepage. Breadth assembled by acquisition this quickly carries real integration debt; weigh it yourself.
• Affineon Health: Left out on continuity: the last verified public milestone is a white-label programme from early 2025 and no 2026 company news surfaced. Included in this list anyway because the workflow it targets — agentic triage of the clinician inbox, grouping and trending results, drafting patient messages, handling refills — is the most under-served workflow in this entire category. If you are commissioning a custom build rather than buying a product, the inbox is where we would start.

The certified API that every EHR must expose is read-only by regulation, and that single fact decides more about what an AI agent can do in your practice than any model choice ever will. Criterion §170.315(g)(10) of the ONC Health IT Certification Program — Standardized API for patient and population services — requires read capability and excludes write. The wording is identical on ONC's test-method page and in its API Resource Guide, both of which we fetched on 23 August 2026.

“‘Read’ services include those that allow authenticated and authorized third-party applications to view EHI through a secure API. These services specifically exclude ‘write’ capabilities, where authenticated and authorized third-party applications would be able to create or modify EHI through a secure API.”

— ONC/ASTP — Standardized API for patient and population services, §170.315(g)(10) test method

Every EHR certified to the Base EHR definition must expose USCDI data over HL7 FHIR R4 and US Core for reading. No certification criterion obliges any EHR to let a third-party agent write. That is a direct consequence of the regulation rather than an inference about any particular vendor, and it produces one sentence a practice owner can carry into every sales meeting:

What Epic actually publishes — stated carefully

It would be easy and wrong to turn this into “Epic forbids writes.” Epic does not. Its own FHIR developer site, fetched 23 August 2026, publishes Create and Update operations for a bounded, enumerated set of resources — including AllergyIntolerance (Create), DocumentReference (Create and Update), Observation (Create and Update), QuestionnaireResponse (Create), and BodyStructure for radiotherapy volume (Create and Update). Write endpoints exist. What exists is a named list, not general chart write access, and anything beyond that list is simply not documented as available.

Epic also documents the deployment path plainly: you can test through the open sandbox or by working with a particular Epic Community Member, and its Vendor Services programme is an optional paid tier offering the ability to request individualised assistance with an app's data exchange. Epic does not publish that programme's fee. Consultancy blogs circulate a figure; we do not print it, because a number that only exists on third-party blogs is not a price, it is a rumour with a currency symbol.

Three consequences that show up in the products

1. 1.Every ambient scribe in this ranking is a copilot, and that is correct design: Abridge, Dragon Copilot, Ambience, Suki, Nabla, Freed, Heidi and DeepScribe all draft; a clinician signs; nothing enters the record unattended. In 2026 the word agent in this market usually means a language model in a workflow that a human still approves. That is not a criticism — given the read-only certified floor it is the only architecture that ships.
2. 2.Suki's order staging is the constraint made visible: Staging an order for clinician sign-off rather than placing it is not a product limitation the vendor is apologising for. It is the shape the regulation forces, and a vendor whose demo shows an order appearing in the chart unattended is either running inside the EHR or should be asked to explain, in writing, which agreement permits it.
3. 3.Suite-native agents escape the constraint, which is their strongest argument: An EHR vendor's own agent does not need the certified API because it is on the inside. That is why healow Genie inside eClinicalWorks, or Epic's own persona agents inside Epic, can do things a third party structurally cannot. The trade is lock-in, and it is a real trade rather than an obvious mistake. If you are already committed to a suite, evaluate the suite's own agent first.

The architectural implications of building on a read-only floor — where the human commit step sits, how audit trails have to be structured, what a BAA actually has to cover — are worked through in detail in our guide to HIPAA-compliant AI agent architecture, which is the companion piece to this ranking for anyone considering a custom build rather than a purchase.

One forward-looking note, hedged because it deserves to be. ASTP/ONC's HTI-4 final rule adopted prior-authorisation certification criteria, and those criteria are themselves read and query shaped rather than write shaped. A further rule, HTI-5, is a proposedderegulatory action that would cut certification criteria — proposed, not in force. Do not let a vendor describe either as a reason the write constraint is about to disappear.

Four regulatory facts decide whether an agent you buy in 2026 is legal, useful and future-proof — and in this area the difference between proposed, in force, vacated and enjoined is the difference between good advice and a lawsuit. Every status below was verified on 23 August 2026.

One honest limitation on the regulatory picture: state AI law is moving fast and we verified Colorado specifically. We did not run a state-by-state sweep, and we will not list other states' AI-in-healthcare laws from memory. Check your own state before deploying a patient-facing agent, and treat Colorado as the shape of what is coming rather than as the only jurisdiction that will have something to say.

Finally, a status note on the payer-side pledge you may have heard about. On 23 June 2025 more than sixty health insurers pledged voluntary prior-authorisation reform on a staggered timetable running through 1 January 2027. It is a voluntary pledge, not a rule. In the AMA's own survey, only 33% of physicians believed it would make a meaningful difference. Do not let it into a business case as though it were an obligation.

What follows is an illustrative scenario, not a client outcome. Every number in it comes from a named primary source cited on this page, and you can rebuild the arithmetic yourself in ten minutes. We do not print invented client results. An article that refuses an unsourceable industry statistic and then asserts an unverifiable client outcome has destroyed its own standing, and a worked scenario costs nothing while delivering the same concreteness.

Now the part a vendor will not put on the slide. In that same survey, only 24% of physicians report that their EHR offers electronic prior authorisation for prescription medications, and physicians report the telephone as the most commonly used method for completing prior authorisations for medical services. The standardised payer prior-authorisation API that would let software do this cleanly is a 1 January 2027 obligation on payers under CMS-0057-F — not on you, and not yet.

So an agent you buy for that 12-provider practice in 2026 is working the same portals and the same phone lines your staff work. It may well do it faster, at any hour, without a queue and without turnover. But it is not integrating with a standard; it is automating a phone call and a web form, and those break when a payer redesigns a portal. That changes three things in how you should buy it: contract length (shorter than the 2027 transition), success measurement (submission success rate per payer, tracked daily, not an ROI figure supplied by the vendor), and staffing plan (the exception queue is the job, and somebody has to own it).

There is a second number in that survey that belongs in every evaluation and appears in almost none of them: 60% of physicians are concerned that AI increases, or will increase, prior-authorisation denial rates. The profession's own measured scepticism, from a named body, with a sample and a date. If you are deploying an AI prior-auth agent while your payer deploys an AI utilisation-management reviewer — which is precisely what Anterior and Cohere Health sell — you are not automating a negotiation, you are automating both sides of one. Set expectations accordingly.

What a practice usually already owns before an agent arrives

Most practices already hold part of this stack, and the door an agent needs is often one a different vendor already has a key to. The dental practice website we built for BH Dental Corp in Beverly Hills books appointments through a NexHealth scheduling integration and collects patient information on HIPAA-compliant intake forms, with insurance verification information and patient-portal integration alongside it. The write into the schedule runs through a practice-management integration, not through a certified API — which is exactly the point of the previous section. Before you buy a second vendor to reach your schedule, find out which of your current vendors already can, and what their contract says about a third party doing it through them.

These systems fail in predictable ways, and the failures are all detectable if you decide in advance what you are watching. The operational mistake practices make is not choosing the wrong vendor — it is deploying without a detection signal and a rollback, so that the first sign of trouble is a complaint rather than a metric.

Build the detection column into your weekly operations review before go-live. A signal nobody looks at is not a control.

Prompt injection is unsolved, and healthcare is unusually exposed

Any agent that reads untrusted input is exposed to prompt injection, and no vendor has solved it — including the ones that say they have. Healthcare has a particular problem here because the untrusted input is constant and arrives in formats nobody controls: inbound faxes, referral packets, scanned insurance cards, patient portal messages, payer correspondence, uploaded records from an outside practice. Every one of those is content authored by someone outside your organisation that an agent is being asked to read and act on.

The correct framing is blast-radius reduction, not prevention. The exposure requires three things together: the agent holds access to sensitive data, it processes untrusted content, and it can communicate outward or take an action that could exfiltrate or damage. Remove any one leg and the exposure collapses. In a practice that usually means the agent that reads inbound documents does not hold the credential that writes to the chart or sends the message; a second, narrower step with a human in it does. That is less elegant than the architecture diagram in the sales deck, and it is the one that survives both a security incident and a compliance review.

Be sceptical of detection claims specifically. A vendor telling you it catches 95% of injection attempts is quoting a number that would be a failing grade in any other area of application security, and it is a number nobody has independently verified in this market either. Ask instead what the agent is permitted to do if a detection fails, because that answer is auditable and the detection rate is not.

An agent may draft the note and stage the order; a licensed clinician must sign both before either enters the record. That sentence is the whole boundary in one line, and it is worth writing into your vendor contract rather than assuming it. The table below expands it into the specific actions a practice has to place on one side or the other before go-live.

Derived from §170.315(g)(10) and the 2026 regulatory picture. Every line is defensible from a source cited on this page.

Two lines in that table deserve emphasis because they are the ones practices get wrong. The first is the disclosure line: from 1 January 2027 a Colorado practice must tell a caller they are speaking with AI, and the FCC has already classified an AI voice as an artificial voice for TCPA purposes — so disclosure is not a courtesy, it is a build requirement in at least one state and a defensive posture everywhere. The second is the crisis-protocol line. A patient who discloses self-harm on a phone line answered by software needs a tested path to a human, and Colorado HB 26-1263 will require the protocol and an annual report on it. Build it before you need it and test it on a schedule.

Notice what the left-hand column also implies about value. Answering the call, identifying the caller, reading the chart, gathering documentation requirements and drafting the packet is the overwhelming majority of the labour in most of these workflows. The commit step is seconds. Any vendor that needs to remove the human commit step to make its ROI work has an ROI problem, not a regulatory one.

For most independent practices the right first move is buying a product with a published price and measuring it against your own baseline — not commissioning a build. A custom agent earns its cost when the workflow is genuinely yours, when no product integrates with the system you actually run, or when the write path you need exists only through a partner agreement a product vendor has not signed. Below are our bands for when that is the case.

Senior-led delivery runs $150 to $225 per hour, and ongoing retainers run $2,500 to $9,500 per month, covering model and dependency upgrades, integration monitoring as your EHR and PM vendors ship releases, evaluation expansion, incident response and a quarterly technical review. Every engagement carries a 30-day post-launch warranty, full source-code and IP ownership transfers to you, and you receive a written scope with a fixed-price phased proposal within 5 business days of the discovery call. Book that call at calendly.com/frenchydigital/discovery-call or call +1 (424) 272-5601, and bring your EHR name, your PM system, your monthly call volume and your denial rate.

Those bands are ours. They are not an industry benchmark, and you should read them exactly the way this article has asked you to read every vendor number on this page: as one firm's published figures, checkable against a written proposal, rather than as a market rate somebody measured.

On sequencing, the order that works is unglamorous. Measure the baseline before you buy anything — minutes per note, calls abandoned, prior-auth submission success by payer, denial rate — because without it you will be arguing about a vendor's numbers instead of your own. Run one workflow, not four. Keep the human commit step. Give the exception queue an owner by name. And re-check the vendor's compliance and pricing pages at renewal, because in this market they change without notice and the cell that was true in August may not be true in February.

Each of these is checkable in a single meeting, and each one has appeared in this market during this review. None of them proves a vendor is bad. All of them are questions whose answers belong in writing before you sign.

• An accuracy, resolution or containment rate presented as a neutral fact: Ask who measured it, against what denominator, and whether you can see the methodology. In this market the honest answer is always that the vendor measured it about itself. That is not disqualifying — publishing it as though a third party had measured it is.
• An ROI figure whose third-party validation is not itself published: One vendor in this roster describes itself as the first ambient solution with third-party validated, CFO-approved ROI, and does not publish the validation. Ask for the report, the validator's name and the scope. If the answer is that it is under NDA, the claim should be under NDA too.
• An unfalsifiable absolute: 100% answer rates. Never places a patient on hold. Every call answered promptly. A claim that cannot fail is marketing language wearing a metric's clothes, and its presence tells you something about how the rest of the deck was written.
• A count of integrations with no names attached: 60-plus EHRs. Deep integration across 15-plus platforms. An unnamed count is not a documented integration. Ask for the list, then ask to speak to a reference on your specific system — because integration with an EHR family is not integration with your instance of it.
• No reachable trust, security or compliance page: Five vendors in this review publish no certification on any page we could reach. That may mean a report exists behind an NDA. It means you ask early, you get the report before the pilot rather than after, and the certification and its scope go in the contract.
• A SOC 2 badge with no type specified: SOC 2 Type I is a point-in-time design assessment; Type II tests operating effectiveness over a period. Three vendors here show a SOC 2 mark without stating the type. Do not upgrade it for them — ask which one, over what period, and by which auditor.
• A write claim with no contract behind it: Ask the direct question: which agreement permits your product to write into our EHR, what is its term, and what does the product do if that access is withdrawn at renewal? A vendor that cannot answer crisply has either not done it before at your EHR or is describing an integration they intend to build.
• A dead product name in the vendor's own competitive deck: If a vendor's comparison slide still lists DAX Copilot, Augmedix, Memora Health or App Orchard as live products, the deck predates several acquisitions. It is a small thing that tells you how recently anyone checked anything.
• Silence about funding history in a category where capital moved: Two vendors we looked at have had no visible new capital since 2024 in a market where a direct competitor raised $120M in June 2026. That is not a reason to avoid them; it is a reason to shorten the contract term, ask about runway and escrow, and avoid making them the single point of failure in patient access.
• A pitch that needs the human out of the loop to work: If removing clinician sign-off is what makes the ROI model close, the model is wrong. The certified API is read-only, the commit step takes seconds, and the labour saving lives in everything before it.

Here is what this article does not know, stated plainly, because a ranking that refuses vendor claims and then hides its own gaps has learned nothing.

• Every compliance and pricing cell is a timestamp, not a permanent fact: All of them were read off vendor pages on 23 August 2026. Vendors change pages without notice. Each cell is re-checkable at the URL given in the sources list, and you should re-check before you sign rather than trusting a table you found in an article.
• Absence of published evidence is not evidence of absence: Five vendors publish no compliance certification on any page we could reach — Ambience, Assort Health, Humata Health, healow Genie and Commure. Several may well hold certificates behind a sales NDA. What we can report is what is published, and we report exactly that.
• SOC 2 type is unstated by three vendors: Tennr, Notable and Adonis display a SOC 2 or AICPA mark without specifying Type I or Type II. This article does not upgrade an unspecified mark to Type II, and neither should your evaluation.
• Funding figures are trade press, not filings: Round sizes and valuations here come from company announcements and trade reporting rather than from regulatory filings. Where a figure came only from trade press we have said so. Treat valuations in particular as directional.
• Three products were dropped for verification reasons, not quality reasons: DeepScribe and Parakeet Health could not be verified from their own trust and pricing pages within this review, and Affineon Health produced no 2026 company news. Any of the three may be right for you. None of them could be ranked on published evidence.
• Two FDA dates rest on secondary corroboration: FDA's own guidance and town-hall pages returned 404 to our automated fetches on the date we checked, so the January 2026 issuance and re-issuance of the Clinical Decision Support guidance are corroborated by law-firm client alerts rather than by FDA's page. The guidance is real; verify the dates yourself before relying on them.
• We did not survey state AI law beyond Colorado: Colorado is the verified example in this article. State AI regulation is moving quickly and we will not list other states' requirements from memory. Check your own state before deploying a patient-facing agent.
• No accuracy, deflection or containment figure appears here as fact: Not because we did not look, but because none is independently verifiable. The precise claim is this: independent randomised trials of ambient scribing exist and we cite one; an independent benchmark of product accuracy does not exist for any product in this ranking.

None of this argues against buying. It argues for buying the way you would buy any other clinical or operational system: measure your baseline first, run one workflow, keep the human commit step, put the compliance answers in the contract rather than the email, and re-check the vendor's published facts at renewal. The practices that get value out of this technology are the ones that found out what they were permitted to do before they found out what the model could do.

And the boundary holds throughout. An agent reads, gathers, drafts, checks and proposes. A licensed person commits anything that enters the chart, changes a clinical decision, or goes to a patient under your name. That is not caution for its own sake — it is the only architecture that survives a prompt injection, a compliance review and a bad week, and it happens to be the one that actually ships.